Two Sigma Investments
HEPA

Two Sigma Investments’s Hepion Pharmaceuticals HEPA Stock Holding History

Two Sigma Investments’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-245
Closed -$485K – 4428
2021
Q2 		$485K Buy
+245
New +$448K ﹤0.01% 3131

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AMC
Asset Management Corp Northbrook, Illinois $128M AUM 6.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Two Sigma Investments's HEPA Position: Q3 2021 in Review

Two Sigma Investments sold out of Hepion Pharmaceuticals (HEPA) in Q3 2021, closing a stake of 245 shares — an estimated $485K sold.

Two Sigma Investments first reported a position in HEPA in Q2 2021 and held it in 1 quarter. The position peaked at $485K in Q2 2021. 37 funds tracked by Wall St. Rank hold HEPA as of Q3 2021.

  • Two Sigma Investments reported no remaining Hepion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Two Sigma Investments sold 245 Hepion Pharmaceuticals shares in Q3 2021, an estimated $485K.
  • Two Sigma Investments first reported a position in Hepion Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Two Sigma Investments's Hepion Pharmaceuticals position peaked at $485K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q3 2021.

Based on Two Sigma Investments's 13F filing for Q3 2021, filed 15 Nov 2021.